The US Food and Drug Administration (FDA) has accepted leading global pharmaceutical company, Teva Pharmaceutical Industries Ltd's New Drug Application (NDA) for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). It is a rare and fatal neurodegenerative disorder caused by the progressive breakdown of nerve cells in the brain that affects about five to seven people per 100,000 in western countries, according to the World Health Organisation.
focus in the areas of pain management and addiction medicine, announced the approval by the US Food and Drug Administration (FDA) of a Supplemental New Drug Application (sNDA) for a new formulation of Onsolis (fentanyl buccal soluble film) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant. Onsolis is separately licensed by BDSI in Taiwan and South Korea.
Dabur India Ltd, in an effort to ensure maximum use of its leading mosquito repellant Odomos, has unveiled the Dengue-Fighters initiative aimed at preventing school-going children across the country. The company along with Apollo Hospitals Group began its campaign in Bengaluru, which will then cover schools across Delhi, Uttar Pradesh, Maharashtra and Tamil Nadu.
A new medication to be launched by the end of this year by US Pharma major Eli Lilly, for diabetic patients in India. A regulatory approval for the upcoming product has already been received by the company. It is also gearing up to introduce another medication in oncology that could be launched by the end of 2016 or early 2017 which has been filed for approvals.
Generic Pramipexole dihydrochloride extended-release tablets for treatment of Parkinson's disease has been launched by Dr Reddy's Laboratories in the US market.
Roche announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumours (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1). The study showed the amount of PD-L1 expressed by a person’s cancer correlated with their response to the medicine. Adverse events were consistent with what has been previously observed for atezolizumab.
(NewsVoir); India’s leading health app, 1mg has announced the commencement of "Jaankari Hai To Jaan Hai", an awareness campaign aimed at informing consumers of cheaper alternatives when it comes to cancer medication. The company kick started this ambitious campaign on the occasion of Youth Awareness Day organised in New Delhi by Yoddhas, a prominent NGO that helps cancer patients.
Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced an exclusive channel collaboration (ECC) to pursue the development and commercialisation of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.
Novartis Healthcare Private Ltd (NHPL) has launched Sequadra iInhaler (indacaterol/glycopyrronium) 110mcg/50mcg, a fixed dose combination (FDC) of two bronchodilating active ingredients, indacaterol maleate, a long-acting beta2-adrenergic agonist (LABA) and glycopyrronium bromide, a long-acting anticholinergic (LAMA), for the treatment of chronic obstructive pulmonary disease (COPD).
BTG plc, an international specialist healthcare company bringing announces that Health Canada has issued a Notice of Compliance approving Varithena (polidocanol injectable foam) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system, above and below the knee.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
